Matthew Onaitis
2017
In 2017, Matthew Onaitis earned a total compensation of $1M as Chief Financial Officer, General Counsel, and Secretary at Cidara Therapeutics, a 6% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $75,700 |
|---|---|
| Option Awards | $308,066 |
| Salary | $340,000 |
| Stock Awards | $278,000 |
| Total | $1,001,766 |
Onaitis received $340K in salary, accounting for 34% of the total pay in 2017.
Onaitis also received $75.7K in non-equity incentive plan, $308.1K in option awards and $278K in stock awards.
Rankings
In 2017, Matthew Onaitis' compensation ranked 8,957th out of 14,666 executives tracked by ExecPay. In other words, Onaitis earned more than 38.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,957 out of 14,666 | 39th |
Division Manufacturing | 3,424 out of 5,772 | 41st |
Major group Chemicals And Allied Products | 1,169 out of 2,075 | 44th |
Industry group Drugs | 933 out of 1,731 | 46th |
Industry Biological Products, Except Diagnostic Substances | 163 out of 313 | 48th |
Source: SEC filing on April 27, 2018.
Onaitis' colleagues
We found three more compensation records of executives who worked with Matthew Onaitis at Cidara Therapeutics in 2017.